A Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring (NCT07700992) | Clinical Trial Compass
RecruitingNot Applicable
A Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring
Italy600 participantsStarted 2026-06-03
Plain-language summary
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by an asymptomatic early phase, late diagnosis, and poor survival, particularly in individuals who develop disease outside the context of early-stage detection. Early detection strategies are currently limited to imaging-based surveillance (MRI and endoscopic ultrasound) in selected high-risk populations, but these approaches are invasive, costly, and suboptimal in sensitivity. The aim of this study is to evaluate circulating cell-free and exosome-bound microRNAs as non-invasive biomarkers of PDAC risk and disease biology
Who can participate
Age range
18 Years – 99 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adult men or women aged ≥18 years at the time of plasma sample collection.
* Classification as at increased risk for pancreatic ductal adenocarcinoma (PDAC) due to familial pancreatic cancer or hereditary pancreatic cancer syndrome
* Classification as at increased risk for pancreatic ductal adenocarcinoma (PDAC) due to the presence of one (or more) mucinous pancreatic cystic lesion(s).
* Availability of stored plasma samples collected as part of routine clinical care or surveillance and archived in the institutional biobank.
* Availability of relevant clinical and demographic data in institutional medical records sufficient to address study objectives.
* Prior provision of informed consent for biobanking and research use of biological samples and data
Exclusion Criteria:
* Absence or insufficient quality/quantity of stored plasma samples for laboratory analysis.
* Lack of clinical data required for cohort classification and/or outcome assessment.
* History of pancreatic surgery or interventional procedures prior to plasma sample collection.
* Concurrent active malignancy at the time of sample collection, other than non-melanoma skin cancer.
* Samples collected outside routine clinical care or not compliant with institutional biobanking and data protection policies.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Sensitivity
Timeframe: Through study completion, an average of 1 year